Hsbc Holdings PLC Has $254,000 Stake in TransMedics Group, Inc. $TMDX

Key Points

• Hsbc Holdings PLC has significantly reduced its stake in TransMedics Group, Inc. by 95.7%, now owning only 3,804 shares after selling 83,694 shares in the first quarter.
• Despite Hsbc's selling, several other institutional investors have increased their positions in TransMedics, with some investment firms seeing substantial growth, such as GAMMA Investing LLC increasing its stake by 551.7%.
• TransMedics Group recently reported an EPS of $0.92, exceeding analysts' expectations, and its revenue increased by 37.7% year-over-year for the last quarter.

Hsbc Holdings PLC reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 95.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,804 shares of the company's stock after selling 83,694 shares during the period. Hsbc Holdings PLC's holdings in TransMedics Group were worth $254,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TMDX. NBC Securities Inc. bought a new position in shares of TransMedics Group in the 1st quarter worth $25,000. Hager Investment Management Services LLC raised its holdings in TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after purchasing an additional 205 shares during the period. CWM LLC lifted its holdings in TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after acquiring an additional 155 shares in the last quarter. GAMMA Investing LLC raised its position in shares of TransMedics Group by 551.7% during the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after purchasing an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. lifted its holdings in shares of TransMedics Group by 46.7% during the 1st quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock valued at $148,000 after purchasing an additional 700 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Down 0.0%

Shares of TMDX traded down $0.04 during midday trading on Friday, hitting $104.01. The stock had a trading volume of 996,736 shares, compared to its average volume of 877,429. The company has a 50 day simple moving average of $118.07 and a two-hundred day simple moving average of $104.46. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $169.29. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of 53.89 and a beta of 2.18. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same quarter last year, the company earned $0.35 EPS. TransMedics Group's revenue for the quarter was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Wall Street Zen lowered TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Canaccord Genuity Group boosted their price objective on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, July 15th. Oppenheimer lifted their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Finally, Stifel Nicolaus assumed coverage on TransMedics Group in a research note on Thursday. They issued a "hold" rating and a $115.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $122.11.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.